Cancer and Metastasis Reviews

Biographical sketch—Dr. Robert Bristow

Preface

Robert G. Bristow

Clinical trials and biomarker development with molecularly targeted agents and radiotherapy

Neesha Dhani, Lillian L. Siu

Clinical biomarkers for hypoxia targeting

Quynh-Thu Le, Don Courter

Molecular markers of radiation-related normal tissue toxicity

Paul Okunieff, Yuhchyau Chen, David J. Maguire, Amy K. Huser

Practical approaches to proteomic biomarkers within prostate cancer radiotherapy trials

Eva Christensen, Kenneth R. Evans, Cynthia Ménard, Melania Pintilie, Robert G. Bristow

Clinical biomarkers of kinase activity: examples from EGFR inhibition trials

Mechthild Krause, Michael Baumann

Clinical target promiscuity: lessons from ras molecular trials

Ramesh Rengan, Keith A. Cengel, Stephen M. Hahn

Clinical biomarkers of angiogenesis inhibition

Aaron P. Brown, Deborah E. Citrin, Kevin A. Camphausen

Use of palliative radiotherapy trials for clinical biomarker development

Jonathan Wan, Michael Milosevic, Anthony M. Brade

Biomarkers for DNA DSB inhibitors and radiotherapy clinical trials

Stanley K. Liu, Peggy L. Olive, Robert G. Bristow

Cancer stem cells: markers or biomarkers?

Wendy A. Woodward, Erik P. Sulman

Clinical biomarkers and imaging for radiotherapy-induced cell death

Marcel Verheij

Multiple biomarker tissue microarrays: bioinformatics and practical approaches

Søren M. Bentzen, Francesca M. Buffa, George D. Wilson

Pancreatic cancer: from molecular pathogenesis to targeted therapy

Alexios Strimpakos, Muhammad W. Saif, Kostas N. Syrigos

The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host

Osvaldo L. Podhajcer, Lorena Benedetti, Maria Romina Girotti, Federico Prada, Edgardo Salvatierra, Andrea S. Llera

Erratum to Experimental frontiers for clinical applications: Novel approaches to understanding mechanisms of lymph node metastases in melanoma

Richard Essner